Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg

American Journal of Clinical Dermatology

Volumn 12, Issue 6, 2011, Pages 403-404

  Damian, Diona L ^a,b,c   Thompson, John F ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

Allergens; Diphencyprone; Malignant melanoma

Indexed keywords

DIPHENCYPRONE;

AGED; CANCER IMMUNOTHERAPY; CANCER SIZE; CASE REPORT; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG MECHANISM; ECZEMA; HUMAN; LETTER; LIMB TUMOR; MALE; MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN PIGMENTATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AGED, 80 AND OVER; CYCLOPROPANES; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 80053519836     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11592600-000000000-00000     Document Type: Letter

References (6)

1. Socrier Y, Lauwers-Cances V, Lamant L, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol 2010; 162 (4): 830-4
2. Hurwitz PJ. Spontaneous regression of metastatic melanoma. Ann Plast Surg 1991; 26 (4): 403-6
3. Damian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009; 50: 266-71
4. Martiniuk F, Damian DL, Thompson JF, et al. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. J Drugs Dermatol 2010; 9 (11): 1368-72
5. Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002; 205 (2): 135-8
6. Powell AM, Robson AM, Russell-Jones R, et al. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with longterm follow-up. Br J Dermatol 2009; 160: 994-8